(NASDAQ: BLTE) Belite Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.16%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.3%.
Belite Bio's earnings in 2026 is -$77,611,000.On average, 11 Wall Street analysts forecast BLTE's earnings for 2026 to be -$117,846,784, with the lowest BLTE earnings forecast at -$153,056,048, and the highest BLTE earnings forecast at -$53,699,045. On average, 11 Wall Street analysts forecast BLTE's earnings for 2027 to be $19,422,138, with the lowest BLTE earnings forecast at -$110,647,571, and the highest BLTE earnings forecast at $237,515,009.
In 2028, BLTE is forecast to generate $154,488,023 in earnings, with the lowest earnings forecast at $79,419,511 and the highest earnings forecast at $294,105,541.